Sec. 4. Penalty with respect to opioids developed using Federal funding
112 words·~1 min read·
/bill/115/hr/5782/ih/section-4·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
If a drug manufacturer or distributor violates subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) (as added by section 2) with respect to an opioid that was developed with the support of Federal funding, in addition to the applicable penalties under such subsection (h), such manufacturer or distributor shall be subject to a civil penalty in an amount equal to the sum of— such Federal funding, regardless of whether the Federal funding was received by the manufacturer or distributor or another entity; plus 25 percent of the total profit such manufacturer or distributor received in connection with manufacturing or distributing such opioid.
Connectionstraces to 1
Traces to 1 document
U.S. Code
Citation graph
cites case law
Sec. 4
Penalty with respect to opioids developed using Federal funding
Cites 1Cited by 0 across 0 sources